UTA2-1 peptide-loaded PD-L silenced dendritic cells

UTA2-1 peptide-loaded PD-L silenced dendritic cells is an investigational cell-based immunotherapy developed by VU University Medical Center. The therapy consists of donor-derived monocyte-derived dendritic cells (DCs) that have been genetically modified using small interfering RNA (siRNA) to silence the co-inhibitory ligands PD-L1 and PD-L2. These modified DCs are subsequently loaded with the UTA2-1 minor histocompatibility antigen (MiHA) peptide. The vaccine is designed as a preemptive strategy following allogeneic stem cell transplantation (allo-SCT) to enhance the graft-versus-tumor effect in patients with hematologic malignancies, such as multiple myeloma and acute myeloid leukemia. By silencing PD-L1 and PD-L2, the dendritic cells are intended to overcome PD-1-mediated T cell inhibition, thereby promoting the robust expansion and activation of UTA2-1-specific CD8+ T cells.

Other names

PD-L silenced UTA2-1 peptide-loaded dendritic cell vaccinedonor-derived PD-L silenced dendritic cells loaded with UTA2-1 peptide